The global cytotoxic drug is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Cytotoxic drugs describe a group of medicines that contain chemicals that acts as a toxin to cell in preventing replication and are used to treat cancer. The rise in the prevalence of lung cancer is anticipated to drive the growth of the global cytotoxic drug market during the forecast period. For instance, according to the data published by the American Cancer Society (ACS) in 2022, approximately 13.0% of all lung cancers are SCLC and, 84.0% are non-small cell lung cancer (NSCLC). Moreover, lung cancer is the leading cause of mortality in both men and women accounting for 25.0% of all cancer mortalities. Further, lung cancer is most prevalent in the geriatric population. As per the ACS in 2022, approximately 236,740 new lung cancer cases have been identified out of which 117,910 are in men and 118,830 are identified in women. Also, 130,180 mortalities occurred due to lung cancer.
A full report of Wooden Decking Market is available at:https://orionmarketreports.com/global-cytotoxic-drug-market/92838/
According to the data published by the American Cancer Society (ACS) in 2022, prostate cancer is the second leading cause of American men. As per the same sources in 2022, approximately 268,490 new prostate cancer have occurred in the US and 34,50 mortalities occurred due to prostate cancer. Moreover, about 1 in 8 men are anticipated to develop prostate cancer during their lifetime. Approximately 6 cases in 10 are diagnosed in men who are 65 years and older, and it is rare in men under 40. Thus , the rise in the prevalence of prostate cancer is anticipated to drive the demand of the global cytotoxic drug market.
Looking towards the demand for the cytotoxic drug, key market players are adopting various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in March 2022, Astrazeneca had received the US FDA approval of Olaparib (lynparza) for the adjuvant treatment of adult patients with suspected BRCA-mutated human epidermal growth factor receptor 2 (HER 2)-negative high-risk early breast cancer who have been treated with adjuvant chemotherapy.
In August 2021, Bristol –Myers Squibb Co. had received the US FDA approval for Nivolumab (opdivo) for the adjuvant treatment with platinum chemotherapy for the treatment of patients with non-small cell lung cancer who are at a high risk of recurrence post radical resection. Further, in October 2021, Merck &Co had received the US FDA approval of pembrolizumab (Keyutruda) in combination with chemotherapy, for the treatment of patients with metastatic cervical cancer. Moreover, in December 2021, Genentech Inc. had received US FDA approval of rituximab in combination with chemotherapy for pediatric patients previously untreated with diffuse large B-cell lymphoma (DLBCL). Thus, such approvals are anticipated to accelerate the growth of the global cytotoxic drug market during the forecast period.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Route of Administration
- By Type
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Johnson & Johnson Services Inc. among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Cytotoxic Drug Market Report by Segment
By Route of Administration
- Oral
- Parenteral
By Application
- Breast Cancer
- Prostate cancer
- Lung Cancer
- Pancreatic cancer
- Others
By Type
- Alkylating Agents
- Antitumor Antibiotics
- Antimetabolities
- Plant Alkaloids
- Others
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
